EIGHTEENTH CONGRESS OF THE 
) 
REPUBLIC OF THE PHILIPPINES 
)
First Regular Session 
)
S. No.
SENATE
928
S e n a te
<0flicr of 
frrcrrtarp
•If AUG 20 «0 32
nK£l\ILt>m:
Introduced by Senator Richard J. Gordon
AN ACT APPROPRIATING THE SUM OF ONE BILLION ONE HUNDRED 
SIXTY-ONE MILLION SEVEN HUNDRED TEN THOUSAND PESOS 
(P I, 161,710,000.00) AS SUPPLEMENTAL APPROPRIATIONS FOR FY 2019
AND FOR OTHER PURPOSES
EXPLANATORY NOTE
On 4 April 2016, the Department of Health (DOH) commenced its school-based 
dengue mass immunization program using the vaccine Dengvaxia manufactured by 
Sanofi Pasteur, the largest company in the world devoted entirely to vaccines. 
Dengvaxia was mass vaccinated in Regions 3 (Central Luzon) and 4 (Southern 
Tagalog), and the National Capital Region, covering about 830,000 children aged nine 
(9) to twelve (12). Notably, Dengvaxia was vaccinated to children without prior 
screening for serostatus to determine whether they have been previously infected by 
dengue.
In July 2016, the World Health Organization released a paper stating, among 
others, that Dengvaxia "may be ineffective or may theoretically even increase the 
future risk of hospitalized or severe dengue illness in those who are seronegative at 
the time of first vaccination regardless of age."


The Blue Ribbon investigation into Dengvaxia fiasco uncovered possible 
adverse effects to persons vaccinated by the drug, undisclosed fully by Sanofi Aventis 
to the world, and by the previous administrators in the DOH to parents and children.
In 29 November 2017, Sanofi Pasteur release a statement saying that "[f]o r 
those not previously infected by dengue virus, however, the analysis found that in the 
longer term, more cases of severe disease could occur following vaccination upon a 
subsequent dengue infection." This recent declaration by Sanofi Pasteur has caused 
panic and despair among parents and guardians of those children who have been 
vaccinated.
There have already been a number of reports of deaths, and also cases of 
severe dengue, in children who were previously vaccinated with Dengvaxia. There is 
an urgent need for the DOH to monitor the health, diagnose whenever the children 
fall sick or ill, provide treatment when required, and rehabilitate all those who were 
adversely affected by Dengvaxia.
The DOH would require budget for its Medical Assistance Program for 
Dengvaxia Patients, in particular, for the monitoring, diagnosis, treatment and 
rehabilitation of possible victims of adverse events following the immunization of the 
Dengvaxia vaccine.
J. GORDON
Senator


EIGHTEENTH CONGRESS OF THE 
)
REPUBLIC OF THE PHILIPPINES 
)
First Regular Session 
)
SENATE
S. No. 
928
-Afuale
#flicr o( t(>f
*19 
AUG 20 WO 32
RECEIVED 0^.
Introduced by Senator Richard 3. Gordon
AN ACT APPROPRIATING THE SUM OF ONE BILLION ONE HUNDRED 
SIXTY-ONE MILLION SEVEN HUNDRED TEN THOUSAND PESOS 
( P l/161/710/000.00) AS SUPPLEMENTAL APPROPRIATIONS FOR FY 2019
AND FOR OTHER PURPOSES
Be it enacted by the Senate and the House o f Representatives o f the Philippines in
Congress assembled:
1 
Section 1. Appropriations. -  The sum of One Billion One Hundred Sixty-One Million
2 
Seven Hundred Ten Thousand Pesos (Pl,161/710,000.00) is hereby appropriated out
3 
of any funds in the National Treasury of the Philippines not otherwise appropriated,
4 
as supplemental appropriations for the FY 2019 Budget.
5
6 
Sec. 2. Assistance to 2016 Dengue Vaccinated Filipinos. -T h e  amount appropriated
7 
herein to fund the assistance to the 2016 Dengue Vaccinated Filipinos shall be used
8 
exclusively for the following programs, projects and activities:
(a) Medical assistance program for 2016 
Dengue 
Vaccinated 
Filipinos 
either 
confined or outpatient
(b) Public health management (assessment
and 
monitoring 
of 
2016 
Dengue 
Vaccinated 
Filipinos, 
including 
the
acquisition of supplies and medicines.
P945,828,000.00


provided that not more than Twenty-Five 
Million Pesos (P25,000,000.00) shall be 
used for the procurement of Dengue 
assistance cards)
(c) Human resources for health deployment 
Total
148.296.000. 00
67.586.000. 
00 
P I,161,710,000.00
1
2
3
4
5
6
7
8 
9
10
11
12
13
14
15
16
17
18
19
20 
21 
22
23
24
25
Sec. 3. Use and Release o f Funds. -T h e  amount appropriated shall be released by 
the Department of Budget and Management (DBM) to the Department of Health 
(DOH) in accordance with budgeting, accounting and auditing laws, rules and 
regulations. The DOH shall issue the guidelines necessary for the proper 
implementation of the foregoing activities and/or projects for the benefit of 2016 
Dengue Vaccinated Filipinos.
Sec. 4. Applicability o f General and Special Provisions in the FY 2019 General 
Appropriations Act. -T he amounts herein appropriated shall be used for the purposes 
indicated and subject to the relevant special and general provisions under Republic 
Act No. 11260 or the FY 2019 General Appropriations Act (GAA).
Sec. 5. Availability o f Appropriations. -T he appropriations authorized in this Act shall 
be available for release and obligation for the purposes specified from the date of the 
effectivity of this Act until fully spent.
Sec. 6. Transparency Provisions. -T he DOH shall ensure that the details of activities 
and/or projects are included as part of the information posted on their transparency 
seals required under Section 106 of the General Provisions under Republic Act No. 
11260 or the FY 2019 GAA.
Sec. 7. Separability Clause. -  If, for any reason or reasons, any part or provisions of 
this Act shall be declared as unconstitutional or invalid, the other parts or provisions 
hereof which are not affected thereby shall continue to be in full force and effect. 
Sec. 8. Effectivity. -T his Act shall take effect immediately upon its publication.


1 
Approved,